Navigation Links
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
Date:2/23/2009

BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assistant Professor, Divisions of Infectious Diseases and Organ Transplantation at Northwestern University Feinberg School of Medicine, during the XI International Symposium on Respiratory Viral Infections taking place in Bangkok, Thailand, February 19 through February 22, 2009. This exploratory Phase 2 trial compared the efficacy and safety of five days of therapy with either 200 mg intravenous (i.v.) peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice-a-day, in patients who required hospitalization related to influenza.

The primary objective of the study was to evaluate time to clinical stability, which is a composite endpoint comprised of normalization of temperature, oxygen saturation, respiratory rate, systolic blood pressure and heart rate. This type of endpoint has previously been used in pneumonia studies, but not in influenza. Secondary objectives of the study included evaluation of viral shedding, mortality, clinical relapse and time to resumption of usual activities. The primary efficacy population was defined as patients with confirmed influenza.

As reported in October 2008, there were no statistically significant differences in any of the efficacy endpoints between the three treatment arms, and peramivir was generally safe and well-tolerated at these dose levels. Evaluation of time to clinical stability, the primary endpoint, showed a median of 23.7 hours for peramivir 200 mg, 37.0 hours for peramivir 400 mg and 28.1 hours for oseltamivir (p=0.306). This exploratory endpoint was driven b
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
6. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
9. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... MILAN , December 17, 2014 ... becoming nothing less than a hub of information concerning the ... A further addition to the recently launched ... world and has now been enriched by a new chapter ... A richly detailed and panoramic hub on ...
(Date:12/17/2014)... and RALEIGH, N.C. , ... Communications, LLC (CTMC), and Integrated Clinical Trial Services, ... and retention for clinical trials announce that they ... Trial Marketing Services (i-CTMS). i-CTMS will provide a ... to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ... (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram Devices (ECG) ... The North America accounts for ... Europe claims approximately 27% (2018). ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
(Date:12/19/2014)... in good shape seems to reduce your risk of high ... more than 57,000 Americans, including more than 35,000 with high ... Those in the poorest shape had a more than ... start of the study, compared to a 50 percent chance ... more than 8,000 people diagnosed with high blood pressure during ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... slightly reduce your risk of developing a form of ... Motrin) and naproxen (Aleve) appear to reduce the risk ... researchers concluded after reviewing nine prior studies. Squamous cell ... These painkillers "have potential as part of ...
(Date:12/17/2014)... 2014 While countless companies tempt patients to ... the potential dangers of their purchase. Not only is the ... qualified doctor, but patients who buy hCG online are typically ... is actually no real hCG present. Illegal internet hCG is ... no safety standards and may contain unknown fillers that can ...
(Date:12/17/2014)... December 17, 2014 HeartMath® Inc., ... on stress, heart rate variability (HRV), heart coherence ... its extensive HRV databases and algorithms to chipset ... will enable HeartMath’s partners to offer its HRV ... research, as well as its normative HRV databases ...
(Date:12/17/2014)... December 17, 2014 Now in its ... the best of the best in senior living and ... only given to communities and agencies that have received ... site. Of the nearly 100,000 providers currently listed on ... of the SeniorAdvisor.com Best of 2015 Awards are located ...
Breaking Medicine News(10 mins):Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3
... ... spread the word about HIV prevention. , ... Chicago, IL (PRWEB) June 22, 2010 -- STDTestExpress , a service dedicated ... free HIV test with the purchase of an 8 Test Panel – a savings of $50. ...
... ... a highly successful wellness center, Dr. Michelle Robin shares seven practices for complete wellness in ... ... they’ll likely share a few tips: eat vegetables, exercise, skip the fast food. Ask if ...
... ... North America., , ... Dallas, TX and Minneapolis, MN (PRWEB) June 22, 2010 -- REPtrax and VendorClear announce ... credentialing organization in the United States. , , ,REPtrax and VendorClear are pioneers in ...
... ... sit up straight and then, one day, you,re able to run through a meadow and ... very first time when they join the Hippotherapy and Therapeutic Riding programs at CAN-TR (Chatham ... Siler City resident, Lisa Reynolds. , ...
... ... President’s Awards, which recognize those individuals who have made a difference in the lives ... mission in various categories. The deadline for nominations is Monday, July 26, 2010. ... (Vocus) June 22, ...
... ... of Duke,s Morris Cancer Clinic on Tuesday morning June 29th to raise awareness and money ... Center. Martin,s Ride is dedicated to fellow cancer patients, doctors, nurses, researchers, friends and family ... ...
Cached Medicine News:Health News:STDTestExpress Highlights National HIV Testing Day with Free HIV Testing 2Health News:STDTestExpress Highlights National HIV Testing Day with Free HIV Testing 3Health News:New Book Offers Seven Low-Cost Habits for a Healthier, Happier Life 2Health News:New Book Offers Seven Low-Cost Habits for a Healthier, Happier Life 3Health News:New Book Offers Seven Low-Cost Habits for a Healthier, Happier Life 4Health News:REPtrax and VendorClear Join Forces 2Health News:Ponies Help Kids with Disabilities Focus on What They CAN Do 2Health News:Ponies Help Kids with Disabilities Focus on What They CAN Do 3Health News:Nominations Wanted for Vascular Disease Foundation President's Awards 2Health News:Cancer and Multiple Sclerosis Survivor Martin Smith's 3,000-mile Bicycle Ride Benefits Cancer Research 2
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin reagent is used for the quantitative determination of albumin concentration in human serum....
AST (SGOT) reagent is used for the quantitative determination of aspartate aminotransferase (AST) in human serum....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen...
Medicine Products: